梯瓦制药Teva Pharmaceutical Industries Limited (TEVA) 2006年年度报告「NYSE」.pdf

1、UNITED STATESSECURITIES AND EXCHANGE COMMISSIONWASHINGTON,D.C.20549FORM 20-FREGISTRATION STATEMENT PURSUANT TO SECTION 12(b)OR(g)OF THE SECURITIES EXCHANGE ACTOF 1934OrANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d)OF THE SECURITIES EXCHANGEACT OF 1934For the fiscal year ended December 31,2006OrTRANSI

2、TION REPORT PURSUANT TO SECTION 13 OR 15(d)OF THE SECURITIES EXCHANGEACT OF 1934For the transition period fromtoOrSHELL COMPANY REPORT PURSUANT TO SECTION 13 OR 15(d)OF THE SECURITIESEXCHANGE ACT OF 1934Date of event requiring this shell company report:Commission File number:0-16174TEVA PHARMACEUTIC

3、AL INDUSTRIES LIMITED(Exact name of Registrant as specified in its charter)N/AISRAEL(Translation of Registrantsname into English)(Jurisdiction of incorporationor organization)5 Basel StreetP.O.Box 3190Petach Tikva 49131,Israel(Address of principal executive offices)Securities registered or to be reg

4、istered pursuant to Section 12(b)of the Act:Title of each className of each exchange on which registeredAmerican Depositary Shares(as evidenced by AmericanDepositary Receipts),each representing one Ordinary Share(Title of Class)The Nasdaq Stock Market LLCSecurities registered or to be registered pur

5、suant to Section 12(g)of the Act:NoneSecurities for which there is a reporting obligation pursuant to Section 15(d)of the Act:NoneIndicate the number of outstanding shares of each of the issuers classes of capital or common stock as of the close of the period covered bythe annual report.793,272,230

6、Ordinary Shares593,800,333 American Depositary SharesIndicate by check mark if the registrant is a well-known seasoned issuer,as defined in Rule 405 of the Securities Act.Yes No If this report is an annual or transition report,indicate by check mark if the registrant is not required to file reports